MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • May 23rd, 2023 • Indivior PLC • Pharmaceutical preparations
THIS MASTER COLLABORATION AGREEMENT (the “Agreement”) is made between the parties listed below on the date of the last signature set out below (the “Effective Date”).
COLLABORATION AGREEMENTMaster Collaboration Agreement • February 2nd, 2010 • Ironwood Pharmaceuticals Inc • Pharmaceutical preparations • New York
Type of Securities: 2,083,334 shares of the Company’s common stock, at $12.00 per share, as may be adjusted pursuant to Section 5.2.2 of the Collaboration Agreement dated September 12, 2007, by and between the Company and the Purchaser, the “Collaboration Agreement”).
SECOND AMENDMENT TO MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • February 22nd, 2024 • Kymera Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Second Amendment to Master Collaboration Agreement (this “Second Amendment”) is made and entered into as of October 21, 2021 (the “Second Amendment Effective Date”), by and between and Vertex Pharmaceuticals Incorporated (“Vertex”) and Kymera Therapeutics, Inc. (“Company”), and amends that certain Master Collaboration Agreement (the “Agreement”), dated as of May 9, 2019 by and between Vertex and Company, as amended by that certain First Amendment to Master Collaboration Agreement, dated as of August 27, 2020. All capitalized terms used, but not otherwise defined, in this Second Amendment shall have the meaning given to them in the Agreement.
IN VITRO DIAGNOSTICS MASTER COLLABORATION AGREEMENT between ASTRAZENECA UK LIMITED and ARCHERDX, INCMaster Collaboration Agreement • June 5th, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • Delaware
This In Vitro Diagnostics Master Collaboration Agreement (this “Agreement”) is made and entered into effective as of 2020 (the “Effective Date”), by and between AstraZeneca UK Limited, a company incorporated in England under no. 03674842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, England (“AZ”), and ArcherDX, INC ., a company incorporated in Delaware whose principal office is at 2477 55th Street, Suite 202 Boulder, CO 80301, USA (“Company”). AZ and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
MASTER COLLABORATION AGREEMENT by and among PROTHENA BIOSCIENCES LIMITED And CELGENE SWITZERLAND LLC Dated as of March 20, 2018Master Collaboration Agreement • August 17th, 2018 • Prothena Corp PLC • Pharmaceutical preparations • New York
This U.S. LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of , 20 (the “Effective Date”) by and between Prothena Biosciences Limited, an Irish limited company (“Prothena”) and Celgene Switzerland LLC, a Delaware limited liability company (“Celgene”)3. Celgene and Prothena are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • July 22nd, 2016 • Blueprint Medicines Corp • Pharmaceutical preparations • Delaware
This Master Collaboration Agreement (this “Agreement”) is effective March 1, 2016, (the “Effective Date”), by and between Ventana Medical Systems, Inc., a Delaware corporation with offices located at 1910 E. Innovation Park Drive, Tucson, AZ 85755 USA (“Ventana”), and Blueprint Medicines Corporation, a Delaware corporation with offices located at 38 Sidney Street, Suite 200, Cambridge, MA 02139 USA (“Blueprint”).
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • June 5th, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • New York
This Master Collaboration Agreement (this “Agreement”) is made effective as of December 6, 2017 (the “Effective Date”), by and between Archer DX, Inc. a Delaware corporation with offices at 2477 55th Street, Suite 202, Boulder, CO 80301 USA (“ARCHER”), and Merck KGaA, a corporation with general partners under German law, with offices at Frankfurter Strasse 250, 64293 Darmstadt, Germany (including its Affiliates, “MRK”). MRK and ARCHER are each sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • June 12th, 2023 • Turnstone Biologics Corp. • Biological products, (no disgnostic substances)
THIS AMENDED AND RESTATED MASTER COLLABORATION AGREEMENT (this “Agreement) is entered into on January 1st, 2021 (hereinafter “Effective Date) by and between H. Lee Moffitt Cancer Center and Research Institute, Inc. a non-profit Florida corporation organized pursuant to Section 1004.43, Florida Statutes, whose address is 12902 Magnolia Drive Tampa, Florida 33612 (“Moffitt”) and Turnstone Biologics Corp., a corporation duly organized under the laws of Delaware whose address is 920 Broadway, 16th Floor, New York, NY 10010 (hereinafter “Company”). Moffitt and Company are hereinafter referred to individually as “Party” and collectively as “Parties.”
EXHIBIT 10.13 MASTER COLLABORATION AGREEMENT This Master Collaboration Agreement ("Agreement") is entered into as of December 20, 1999 ("Effective Date") by and between MATSUSHITA-KOTOBUKI ELECTRONICS INDUSTRIES, LTD., a corporation organized under...Master Collaboration Agreement • March 28th, 2000 • Replaytv Inc • Cable & other pay television services
Master Collaboration AgreementMaster Collaboration Agreement • October 5th, 2010 • KL Energy Corp • Services-engineering, accounting, research, management • California
This Master Collaboration Agreement (“Agreement”) is made as of August 30, 2010 (the “Effective Date”), by and between KL Energy Corporation, a Nevada corporation with offices at 306 East St. Joseph Street, Suite 200, Rapid City, South Dakota 57701 (the “Company”), and add blue Consultoria Ltda., a company organized in Brazil with offices at Rua Joaquim Nabuco, 47, office 81, Brooklin, City of São Paulo, State of São Paulo, 04621-000 (“Add Blue”).
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • May 8th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances)
This Master Collaboration Agreement (this “Agreement”) is made effective as of July 10, 2015 by and between ADAPTIVE BIOTECHNOLOGIES CORPORATION, a Washington corporation (“Adaptive”), and Adaptimmune Limited, a limited company formed under the laws of England and Wales (“Collaborator” and together with Adaptive, the “Parties”).
AMENDMENT NO. 2 to MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • May 28th, 2021 • Century Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to Master Collaboration Agreement (the “Amendment No. 2”) is made and effective as of March 23, 2021 (the “Amendment No. 2 Effective Date”) between Century Therapeutics, Inc. (f/k/a Century Therapeutics, LLC), a Delaware corporation (“Century”) having a principal place of business at 3675 Market Street, Philadelphia, PA 19104 USA, and FUJIFILM Cellular Dynamics, Inc., a Wisconsin corporation (“FCDI”) having an address at 525 Science Drive, Madison, WI 53711 USA, and amends the Master Collaboration Agreement entered into between Century and CDI, signed as of October 21, 2019 and as amended by that certain Amendment No. 1 to Master Collaboration Agreement, dated as of July 17, 2020 (the “Collaboration Agreement”). All capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Collaboration Agreement.
MASTER COLLABORATION AGREEMENT by and between CELGENE CORPORATION and KYN THERAPEUTICS INC. Dated as of January 11, 2019Master Collaboration Agreement • March 5th, 2021 • Ikena Oncology, Inc. • Biological products, (no disgnostic substances) • New York
This MASTER COLLABORATION AGREEMENT (this “Agreement”) is entered into and made effective as of January 11, 2019 (the “Collaboration Effective Date”) by and between Celgene Corporation, a Delaware corporation (“Celgene”), and Kyn Therapeutics Inc., a Delaware corporation (“Company”). Celgene and Company are each referred to herein by name or as a “Party”, or, collectively, as the “Parties”.
Amendment No. 1Master Collaboration Agreement • May 4th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to Amended and Restated Master Collaboration Agreement (this “Amendment No. 1”) is made as of February 17, 2016 (“Amendment No. 1 Effective Date”), by and between bluebird bio, Inc. (“Bluebird”), a Delaware corporation, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), and Celgene European Investment Company LLC (“Celgene Europe”), a Delaware limited liability company (Celgene Europe and Celgene Corp., together, “Celgene”). Each of Bluebird and Celgene may be referred to herein as a “Party” or together as the “Parties”. Reference is hereby made to that certain Amended and Restated Master Collaboration Agreement, by and between Bluebird, Celgene Corp. and Celgene Europe, dated June 3, 2015 (the “Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • February 24th, 2021 • Kura Oncology, Inc. • Pharmaceutical preparations • California
This Master Collaboration Agreement (this “Agreement”) is effective as of January 4, 2021 (the “Effective Date”) and is made by and between Illumina, Inc., a Delaware corporation (“Illumina”) and Kura Oncology, Inc., a Delaware corporation (“Partner”). Illumina and Partner may be referred to each individually as a “Party” and collectively as the “Parties.”
MASTER COLLABORATION AGREEMENT for Companion DiagnosticsMaster Collaboration Agreement • May 16th, 2022 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations
SYROS is a biopharmaceutical company engaged in the research and development of products for the treatment of human disease and conditions, including cancer;
AMENDMENT NO. 1 TO MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • May 28th, 2021 • Century Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO MASTER COLLABORATION AGREEMENT (this “Amendment No. 1”) is made as of July 17, 2020 (“Amendment No. 1 Signing Date”) by and between CENTURY THERAPEUTICS, LLC, having a principal place of business at 3675 Market St., Philadelphia, PA 19104 USA (“Century”) and FUJIFILM Cellular Dynamics, Inc., having a principal place of business at 525 Science Drive, Madison WI 53711, USA (“FCDI”). Century and FCDI are each referred to as a “Party” and collectively referred to as the “Parties.”
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • September 8th, 2023 • Hong Kong
MASTER COLLABORATION AGREEMENT By and Between Qualcomm Technologies, Inc. AND Veoneer US, Inc.Master Collaboration Agreement • February 19th, 2021 • Veoneer, Inc. • Motor vehicle parts & accessories • New York
This Master Collaboration Agreement (“Agreement”), dated as of January 25, 2021 (the “Effective Date”), is entered into by and between Veoneer, Inc., a corporation organized under the laws of Delaware (together with its Affiliates, “Veoneer”), and Qualcomm Technologies, Inc., a corporation organized under the laws of Delaware (together with its Affiliates, “QTI”). Each of Veoneer and QTI may be referred to in this Agreement as a “Party.”
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • November 10th, 2016 • Blueprint Medicines Corp • Pharmaceutical preparations • Delaware
Blueprint is a global pharmaceutical company engaged in the research, development, manufacture and commercialization of pharmaceutical products to treat disease;
MASTER COLLABORATION AGREEMENT by and between SomaLogic, Inc. and Novartis Pharma AG September 20, 2019Master Collaboration Agreement • June 25th, 2021 • CM Life Sciences II Inc. • Services-commercial physical & biological research • New York
This Master Collaboration Agreement (the “Agreement”) is made effective as of the last date of signature set forth below (the “Effective Date”) between SOMALOGIC, INC., a Delaware corporation having its principal office ‘at 2945 Wilderness Place, Boulder, CO 80301 (“SomaLogic”), and Novartis Pharma AG, a Swiss company with its principal place of business at Lichtstrasse 35, Basel, Switzerland 4056 (“Novartis”). SomaLogic and Novartis may be referred to herein individually as a “Party” and together as the “Parties”. Capitalized terms set forth herein have the meanings set forth in the body of this Agreement or in Appendix 1 (Definitions).
Amendment No. 2 to Amended and Restated Master Collaboration AgreementMaster Collaboration Agreement • September 9th, 2021 • 2seventy Bio, Inc. • Pharmaceutical preparations
This Amendment No. 2 to Amended and Restated Master Collaboration Agreement (this “Amendment No. 2”)is made as of September 28,2017 (“Amendment No. 2 Effective Date”), by and between bluebird bio, Inc. (“Bluebird”), a Delaware corporation, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”),and Celgene European Investment Company LLC (“Celgene Europe”), a Delaware limited liability company (Celgene Europe and Celgene Corp., together, “Celgene”). Each of Bluebird and Celgene may be referred to herein as a “Party” or together as the “Parties”. Reference is hereby made to that certain Amended and Restated Master Collaboration Agreement, by and between Bluebird, Celgene Corp. and Celgene Europe, dated June 3, 2015, as amended (the “Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
ContractMaster Collaboration Agreement • July 3rd, 2012
Enclosed please find ALCMI's Master Collaboration Agreement (MCA). This rather comprehensive MCA brings member institutions into ALCMI as a consortium, and specific research projects are incorporated via a simple one page Research Study Agreement (study name, PI, institutional and ALCMI signatures). To date, the MCA has been executed by the following institutions and organizations:
Master Collaboration AgreementMaster Collaboration Agreement • March 30th, 2022
About this template agreement This template supports the implementation of its Commercial Arrangements, Sponsorship and Donations Policy. It has been designed by the NSW Department of Education to enable a business unit or directorate to facilitate collaboration between external parties and multiple schools on projects that benefit schools and students. When to use and not use this template This template can be used for projects involving: multiple schools each participating in the project (either centrally coordinated or acting independently) one external organisation that is not a NSW government agency both the external organisation and the schools that participate in the project contribute to the achievement of an objective, and no payment of money by the Department or its schools (or students or parents) to the external organisation or vice versa. This template should not be used for projects involving: the Department or its schools (or students or parents) paying an external organ
Companion Diagnostics MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • May 12th, 2015 • Tokai Pharmaceuticals Inc • Pharmaceutical preparations • New York
AMENDMENT NO. 3 TO MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • May 28th, 2021 • Century Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 3 TO MASTER COLLABORATION AGREEMENT (this “Amendment No. 3”) is made as of 29th March, 2021 (the “Amendment No. 3 Signing Date”) by and between CENTURY THERAPEUTICS, INC. (f/k/a Century Therapeutics, LLC) having a principal place of business at 3675 Market St., Philadelphia, PA 19104 USA (“Century”) and FUJIFILM Cellular Dynamics, Inc., having a principal place of business at 525 Science Drive, Madison WI 53711, USA (“FCDI”). Century and FCDI are each referred to as a “Party” and collectively referred to as the “Parties.”
ACCELERATE TECHNOLOGIES PTE LTD AND APTORUM GROUP LIMITED AND AENEAS CAPITAL LIMITEDMaster Collaboration Agreement • April 24th, 2019 • Aptorum Group LTD • Pharmaceutical preparations
AMENDMENT NO. 1 TO MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • November 9th, 2015 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
This First Amendment (this “Amendment”), effective as of the date of the last signature set forth below (the “Amendment Effective Date”), amends that certain Master Collaboration Agreement dated January 11, 2014 (the “Master Agreement”), and certain of the License Terms attached thereto, by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). The Master Agreement, together with the License Terms attached thereto, are referred to collectively herein as the “Collaboration Agreement.” Alnylam and Genzyme are individually referred to herein as a “Party” and collectively referred to as the “Parties”.
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • February 13th, 2012 • Ontario
majority of its employees, operations and revenue located and earned in the Province of Ontario, is a corporation under the Canada Business Corporations Act.
COLLABORATION AGREEMENT by and between MICROBIA, INC. and FOREST LABORATORIES, INC. September 12, 2007 MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • June 13th, 2013 • Forest Laboratories Inc • Pharmaceutical preparations • New York
This MASTER COLLABORATION AGREEMENT (the “Agreement”) is entered into on this 12th day of September, 2007 (the “Effective Date”), by and among Microbia, Inc., a Delaware corporation (“Microbia”) and Forest Laboratories, Inc. (“Forest”). Microbia and Forest may each be referred to herein individually as a “Party” and collectively as the “Parties.”
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • May 28th, 2021 • Century Therapeutics, Inc. • Biological products, (no disgnostic substances) • Wisconsin
THIS MASTER COLLABORATION AGREEMENT (together with its Exhibit(s), this “Agreement”) is made as of October 21, 2019 (the “Signing Date”) by and between CENTURY THERAPEUTICS, LLC, having a principal place of business at 3675 Market St., Philadelphia, PA 19104 USA (“Century”) and FUJIFILM Cellular Dynamics, Inc., having a principal place of business at 525 Science Drive. Madison WI 53711. USA (“FCDI”). Century and FCDI are each referred to as a “Party” and collectively referred to as the “Parties.”
MASTER COLLABORATION AGREEMENT UNIVERSITY OF :MICHIGAN -- SHANGHAI nAO TONG UNIVERSITYMaster Collaboration Agreement • September 4th, 2020
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Master Collaboration Agreement • June 22nd, 2020 • Kymera Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Master Collaboration Agreement (this “Agreement”) is entered into as of May 9, 2019 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of The Commonwealth of Massachusetts (“Vertex”) and Kymera Therapeutics, Inc., a corporation organized under the laws of The State of Delaware (“Company”). Vertex and Company each may be referred to herein individually as a “Party” or collectively as the “Parties.”
Amendment No. 2 to Amended and Restated Master Collaboration AgreementMaster Collaboration Agreement • November 1st, 2017 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to Amended and Restated Master Collaboration Agreement (this “Amendment No. 2”) is made as of September 28, 2017 (“Amendment No. 2 Effective Date”), by and between bluebird bio, Inc. (“Bluebird”), a Delaware corporation, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), and Celgene European Investment Company LLC (“Celgene Europe”), a Delaware limited liability company (Celgene Europe and Celgene Corp., together, “Celgene”). Each of Bluebird and Celgene may be referred to herein as a “Party” or together as the “Parties”. Reference is hereby made to that certain Amended and Restated Master Collaboration Agreement, by and between Bluebird, Celgene Corp. and Celgene Europe, dated June 3, 2015, as amended (the “Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.
MASTER COLLABORATION AGREEMENT BETWEENMaster Collaboration Agreement • March 13th, 2020 • Molecular Templates, Inc. • Pharmaceutical preparations • Massachusetts
This Master Collaboration Agreement (this “Agreement”) is entered into as of November 18, 2019 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of the Commonwealth of Massachusetts (“Vertex”) and Molecular Templates Inc., a corporation organized under the laws of the State of Delaware (“Company”). Vertex and Company each may be referred to herein individually as a “Party” or collectively as the “Parties.”
